Literature DB >> 22554708

Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema.

Johanna Stoevesandt1, Johannes Hain, Andreas Kerstan, Axel Trautmann.   

Abstract

BACKGROUND: Severe anaphylaxis in Hymenoptera venom allergy has been associated with a number of risk factors including elevation of baseline serum tryptase (BST), older age, concomitant diseases, and concurrent medication.
OBJECTIVE: The aim of this study was to evaluate indicators and risk factors for severe anaphylaxis due to Hymenoptera field stings with an emphasis on details related to the sting reaction and concurrent medication.
METHODS: In this single-center observational cohort study, we included 657 consecutive patients fulfilling the criteria for venom immunotherapy. Severity of sting-induced anaphylaxis was analyzed in relation to patient-specific risk factors (age and sex, preexisting cardiopulmonary conditions, cardiovascular medication) and details related to the sting reaction (culprit insect, localization of the sting, time interval to onset of symptoms, and presence or absence of cutaneous involvement). BST was determined in a subgroup of patients with moderate to severe anaphylaxis.
RESULTS: Four significant indicators and risk factors of severe anaphylaxis were identified (P < .001): (1) elevation of BST, (2) absence of urticaria or angioedema during anaphylaxis, (3) time interval of less than 5 minutes from sting to onset of symptoms, and (4) senior age. The absence of urticaria/angioedema is significantly related to BST elevation (P = .02). No relationship could be established between the severity of anaphylaxis and comorbidities or concurrent cardiovascular medication.
CONCLUSIONS: Absence of urticaria/angioedema is an indicator of severe anaphylaxis and possibly mastocytosis, requiring determination of BST. Study data do not provide evidence for an aggravation of sting-induced anaphylaxis by concurrent beta-blockade or angiotensin-converting enzyme inhibition.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22554708     DOI: 10.1016/j.jaci.2012.03.024

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

Review 1.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

Review 2.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 3.  Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?

Authors:  A Matito; M Carter
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

Review 4.  Particularities of allergy in the Tropics.

Authors:  Luis Caraballo; Josefina Zakzuk; Bee Wah Lee; Nathalie Acevedo; Jian Yi Soh; Mario Sánchez-Borges; Elham Hossny; Elizabeth García; Nelson Rosario; Ignacio Ansotegui; Leonardo Puerta; Jorge Sánchez; Victoria Cardona
Journal:  World Allergy Organ J       Date:  2016-06-27       Impact factor: 4.084

5.  A multicenter anaphylaxis registry in Korea: Clinical characteristics and acute treatment details from infants to older adults.

Authors:  Kyunguk Jeong; Young-Min Ye; Sang-Ha Kim; Kyung Won Kim; Jeong Hee Kim; Ji-Won Kwon; Song-I Yang; So-Yeon Lee; Eun Hee Chung; Mi-Ae Kim; Yoon Hee Kim; Hye-Young Kim; Gwang Cheon Jang; Joo-Hee Kim; Eunjoo Lee; Jihyun Kim; Kangmo Ahn; Yoon-Seok Chang; Gyu-Young Hur; Jeongmin Lee; Taek Ki Min; Bok-Yang Pyun; Kyung Hee Park; Jaechun Lee; Tae Won Song; Hye Mi Jee; Yoo Seob Shin; Dankyu Yoon; Jeom-Kyu Lee; Sooyoung Lee
Journal:  World Allergy Organ J       Date:  2020-08-11       Impact factor: 4.084

6.  Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom.

Authors:  Johanna Stoevesandt; Bernd Hofmann; Johannes Hain; Andreas Kerstan; Axel Trautmann
Journal:  Allergy Asthma Clin Immunol       Date:  2013-09-02       Impact factor: 3.406

7.  International consensus on (ICON) anaphylaxis.

Authors:  F Estelle R Simons; Ledit Rf Ardusso; M Beatrice Bilò; Victoria Cardona; Motohiro Ebisawa; Yehia M El-Gamal; Phil Lieberman; Richard F Lockey; Antonella Muraro; Graham Roberts; Mario Sanchez-Borges; Aziz Sheikh; Lynette P Shek; Dana V Wallace; Margitta Worm
Journal:  World Allergy Organ J       Date:  2014-05-30       Impact factor: 4.084

8.  Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients.

Authors:  Danielle Fehr; Sara Micaletto; Thomas Moehr; Peter Schmid-Grendelmeier
Journal:  Clin Transl Allergy       Date:  2019-10-11       Impact factor: 5.871

Review 9.  New trends in anaphylaxis.

Authors:  Margitta Worm; Gunter Sturm; Jörg Kleine-Tebbe; Ewa Cichocka-Jarosz; Victoria Cardona; Ioana Maris; Sabine Dölle
Journal:  Allergo J Int       Date:  2017-11-15

Review 10.  Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?

Authors:  Umit Murat Sahiner; Stephen R Durham
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.